ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50 Day Moving Average of $2.16

ProQR Therapeutics (NASDAQ:PRQR) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.16 and traded as high as $2.20. ProQR Therapeutics shares last traded at $2.05, with a volume of 319,416 shares.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of ProQR Therapeutics in a report on Thursday, March 14th. Chardan Capital raised their price objective on shares of ProQR Therapeutics from $2.00 to $2.50 and gave the stock a “buy” rating in a research note on Thursday, March 14th. Finally, StockNews.com lowered shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, ProQR Therapeutics has an average rating of “Moderate Buy” and an average target price of $3.56.

ProQR Therapeutics Trading Down 5.0 %

The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.54 and a current ratio of 3.54. The stock has a market cap of $154.58 million, a P/E ratio of -5.15 and a beta of 0.21. The company has a 50-day simple moving average of $2.15 and a 200-day simple moving average of $1.87.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $3.54 million during the quarter, compared to analysts’ expectations of $27.88 million. ProQR Therapeutics had a negative net margin of 431.65% and a negative return on equity of 56.71%. On average, sell-side analysts forecast that ProQR Therapeutics will post -0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PRQR. Monaco Asset Management SAM grew its holdings in ProQR Therapeutics by 58.9% during the third quarter. Monaco Asset Management SAM now owns 377,517 shares of the biopharmaceutical company’s stock valued at $491,000 after purchasing an additional 140,000 shares during the period. Jane Street Group LLC increased its position in shares of ProQR Therapeutics by 198.0% in the 1st quarter. Jane Street Group LLC now owns 55,868 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 37,121 shares in the last quarter. GSA Capital Partners LLP increased its position in shares of ProQR Therapeutics by 69.0% in the 3rd quarter. GSA Capital Partners LLP now owns 74,084 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 30,248 shares in the last quarter. Virtu Financial LLC bought a new position in ProQR Therapeutics during the fourth quarter worth about $69,000. Finally, Mariner LLC acquired a new position in ProQR Therapeutics in the fourth quarter valued at about $68,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).